Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
NCT ID: NCT02455726
Last Updated: 2015-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
150 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-09-30
Study Completion Date
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Magnesium exerts analgesic effects in several animal pain models and in patients affected by acute postoperative pain and chronic pain of neuropathic origin. There is no evidence that magnesium can modulate pain in patients with peripheral arterial occlusive disease (PAOD).
We describe the protocol of a single-center randomized double-blind clinical trial aimed at assessing the efficacy of oral magnesium supplementation in controlling severe pain in patients with advanced PAOD.
We describe the protocol of a single-center randomized double-blind clinical trial aimed at assessing the efficacy of oral magnesium supplementation in controlling severe pain in patients with advanced PAOD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnesium as an Adjuvant Agent for Postoperative Pain
NCT05947760
Pain, Postoperative
RECRUITING
PHASE4
Comparison of Postoperative Analgesic Effect of Intrathecal Magnesium and Fentanyl Added to Bupivacaine in Patients Undergoing Lower Limb Orthopedic Surgery
NCT01205997
Post Operative Pain
COMPLETED
PHASE1/PHASE2
Pain and Magnesium
NCT03063931
Neuropathic Pain Induced by Mastectomy
UNKNOWN
PHASE2
Intrathecal Magnesium and Postoperative Analgesia
NCT00560092
Total Hip Replacement
COMPLETED
PHASE3
The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients
NCT01433081
Pain
Opioid Use, Unspecified, Uncomplicated
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Adult patients admitted to our Acute Pain Service for intractable pain will be eligible if they are affected by PAOD at stages III and IV of Lèriche-Fontaine classification, and are opioid-naïve.
* Patients enrolled will be randomized to the control group, treated with standard therapy, consisting of an oral administration of oxycodone 5 mg and pregabalin 25 mg per day plus placebo (fructose 10 g) twice a day for two weeks, or to the experimental group, treated with magnesium oxide 300 mg twice a day.
* Randomization will be computer-generated, with allocation concealment obtained using opaque, sequentially numbered and sealed envelopes. Trials participants, care providers, data collectors, outcome assessors and data analysts will be blinded to treatment allocation.
* Patients will be evaluated on the day of hospital admission (day 0) and on days 2, 4, 6, 8, 12, and 14 with the following information being collected: daily oxycodone dose received; patient's perceived average and maximum pain using the Numerical Rating Scale (NRS: 0=no pain to 10=worst possible pain); pain relief using Pain Relief Scale (PRS: 0% no pain relief to 100% complete pain relief); characteristics of the pain, using the Neuropathic Pain Scale (NPS: 10 items); impact of pain on the patient's daily activities, using the Brief Pain Inventory (BPI; 9 items).
* A sample size calculation performed for the primary outcome showed that 150 patients (75 per group) are needed to achieve 90% power to detect a minimum reduction of 30% in oxycodone dosage in the experimental group, after allowing for a drop-out rate of around 20%.
* Ethical approval of the study protocol has been obtained from Comitato Etico Provinciale di Brescia, Brescia, Italy.
* Patients enrolled will be randomized to the control group, treated with standard therapy, consisting of an oral administration of oxycodone 5 mg and pregabalin 25 mg per day plus placebo (fructose 10 g) twice a day for two weeks, or to the experimental group, treated with magnesium oxide 300 mg twice a day.
* Randomization will be computer-generated, with allocation concealment obtained using opaque, sequentially numbered and sealed envelopes. Trials participants, care providers, data collectors, outcome assessors and data analysts will be blinded to treatment allocation.
* Patients will be evaluated on the day of hospital admission (day 0) and on days 2, 4, 6, 8, 12, and 14 with the following information being collected: daily oxycodone dose received; patient's perceived average and maximum pain using the Numerical Rating Scale (NRS: 0=no pain to 10=worst possible pain); pain relief using Pain Relief Scale (PRS: 0% no pain relief to 100% complete pain relief); characteristics of the pain, using the Neuropathic Pain Scale (NPS: 10 items); impact of pain on the patient's daily activities, using the Brief Pain Inventory (BPI; 9 items).
* A sample size calculation performed for the primary outcome showed that 150 patients (75 per group) are needed to achieve 90% power to detect a minimum reduction of 30% in oxycodone dosage in the experimental group, after allowing for a drop-out rate of around 20%.
* Ethical approval of the study protocol has been obtained from Comitato Etico Provinciale di Brescia, Brescia, Italy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Peripheral Arterial Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mg-group
Standard therapy plus magnesium oxide.
* Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
* A rescue dose: paracetamol 1g (maximum dose 3 g per day).
Group Type
EXPERIMENTAL
Magnesium oxide
Intervention Type
DIETARY_SUPPLEMENT
Oral magnesium oxide 300 mg twice a day
Oxycodone
Intervention Type
DRUG
Oxycodone hydrochloride 5 mg at 8 am
Pregabalin
Intervention Type
DRUG
Pregabalin 25 mg at 8 pm
C-group
Standard therapy plus fructose.
* Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
* A rescue dose: paracetamol 1g (maximum dose 3 g per day).
Group Type
PLACEBO_COMPARATOR
Fructose
Intervention Type
DIETARY_SUPPLEMENT
Oral fructose 10 g twice a day
Oxycodone
Intervention Type
DRUG
Oxycodone hydrochloride 5 mg at 8 am
Pregabalin
Intervention Type
DRUG
Pregabalin 25 mg at 8 pm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnesium oxide
Oral magnesium oxide 300 mg twice a day
Intervention Type
DIETARY_SUPPLEMENT
Fructose
Oral fructose 10 g twice a day
Intervention Type
DIETARY_SUPPLEMENT
Oxycodone
Oxycodone hydrochloride 5 mg at 8 am
Intervention Type
DRUG
Pregabalin
Pregabalin 25 mg at 8 pm
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Oxycontin, Mundipharma Pharmaceutic
Lyrica, Pfizer Italia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adult patients (18 years or above)
* PAOD at stages III and IV according to the Lèriche-Fontaine classification
* no treatment with opioids at the time of recruitment
* PAOD at stages III and IV according to the Lèriche-Fontaine classification
* no treatment with opioids at the time of recruitment
Exclusion Criteria
* renal failure (serum creatinine ≥ 2.0 mg/dl);
* congestive heart failure (New York Heart Association, NYHA \> 3);
* treatment with digoxin and/or calcium channel blockers;
* pre-existing neuromuscular diseases;
* chronic diarrhea;
* acute limb ischemia successfully treated with interventional angiography, Fogarty embolectomy and/or surgical revascularization.
* congestive heart failure (New York Heart Association, NYHA \> 3);
* treatment with digoxin and/or calcium channel blockers;
* pre-existing neuromuscular diseases;
* chronic diarrhea;
* acute limb ischemia successfully treated with interventional angiography, Fogarty embolectomy and/or surgical revascularization.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Monica Aida Venturini
MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monica A Venturini, Doctor
Role: PRINCIPAL_INVESTIGATOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Dowell D, Kunins HV, Farley TA. Opioid analgesics--risky drugs, not risky patients. JAMA. 2013 Jun 5;309(21):2219-20. doi: 10.1001/jama.2013.5794. No abstract available.
Reference Type
BACKGROUND
Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1.
Reference Type
BACKGROUND
Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J. 1984 Jul;108(1):188-93. doi: 10.1016/0002-8703(84)90572-6. No abstract available.
Reference Type
BACKGROUND
Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005 Apr;179(1):4-29. doi: 10.1007/s00213-005-2200-z. Epub 2005 Feb 25.
Reference Type
BACKGROUND
Recio-Pinto E, Castillo C. Peripheral N-methyl-D-aspartate receptors as possible targets for chronic pain treatment. Techniques in Reg Anesth & Pain Manag 2010;14:48-58
Reference Type
BACKGROUND
Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage. 2000 Nov;20(5):358-73. doi: 10.1016/s0885-3924(00)00213-x.
Reference Type
BACKGROUND
Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain. 2000 Jun;16(2 Suppl):S73-9. doi: 10.1097/00002508-200006001-00013.
Reference Type
BACKGROUND
De Kock MF, Lavand'homme PM. The clinical role of NMDA receptor antagonists for the treatment of postoperative pain. Best Pract Res Clin Anaesthesiol. 2007 Mar;21(1):85-98. doi: 10.1016/j.bpa.2006.12.006.
Reference Type
BACKGROUND
Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003 Oct;97(4):1108-1116. doi: 10.1213/01.ANE.0000081061.12235.55.
Reference Type
BACKGROUND
Nechifor M. Magnesium involvement in pain. Magnes Res. 2011 Dec;24(4):220-2. doi: 10.1684/mrh.2011.0296. No abstract available.
Reference Type
BACKGROUND
Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Mansoori M, Soltani N. Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats. Diabetes Res Clin Pract. 2006 Jul;73(1):17-22. doi: 10.1016/j.diabres.2005.12.004. Epub 2006 Jan 18.
Reference Type
BACKGROUND
Rondon LJ, Privat AM, Daulhac L, Davin N, Mazur A, Fialip J, Eschalier A, Courteix C. Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain. J Physiol. 2010 Nov 1;588(Pt 21):4205-15. doi: 10.1113/jphysiol.2010.197004.
Reference Type
BACKGROUND
Begon S, Pickering G, Eschalier A, Dubray C. Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology. 2002 Mar;96(3):627-32. doi: 10.1097/00000542-200203000-00019.
Reference Type
BACKGROUND
Bujalska M, Makulska-Nowak H, Gumulka SW. Magnesium ions and opioid agonists in vincristine-induced neuropathy. Pharmacol Rep. 2009 Nov-Dec;61(6):1096-104. doi: 10.1016/s1734-1140(09)70172-0.
Reference Type
BACKGROUND
Ulugol A, Aslantas A, Ipci Y, Tuncer A, Hakan Karadag C, Dokmeci I. Combined systemic administration of morphine and magnesium sulfate attenuates pain-related behavior in mononeuropathic rats. Brain Res. 2002 Jul 5;943(1):101-4. doi: 10.1016/s0006-8993(02)02618-5.
Reference Type
BACKGROUND
Chen Y, Zhang Y, Zhu YL, Fu PL. Efficacy and safety of an intra-operative intra-articular magnesium/ropivacaine injection for pain control following total knee arthroplasty. J Int Med Res. 2009 Nov-Dec;37(6):1733-41. doi: 10.1177/147323000903700609.
Reference Type
BACKGROUND
Bondok RS, Abd El-Hady AM. Intra-articular magnesium is effective for postoperative analgesia in arthroscopic knee surgery. Br J Anaesth. 2006 Sep;97(3):389-92. doi: 10.1093/bja/ael176. Epub 2006 Jul 11.
Reference Type
BACKGROUND
Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007 Mar-Apr;31(2):167-73. doi: 10.1007/s00266-006-0194-5.
Reference Type
BACKGROUND
Nechifor M. Magnesium in major depression. Magnes Res. 2009 Sep;22(3):163S-166S.
Reference Type
BACKGROUND
Murck H. Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back. J Psychiatr Res. 2013 Jul;47(7):955-65. doi: 10.1016/j.jpsychires.2013.02.015. Epub 2013 Mar 26.
Reference Type
BACKGROUND
Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013 Jan;68(1):79-90. doi: 10.1111/j.1365-2044.2012.07335.x. Epub 2012 Nov 1.
Reference Type
BACKGROUND
Seyhan TO, Tugrul M, Sungur MO, Kayacan S, Telci L, Pembeci K, Akpir K. Effects of three different dose regimens of magnesium on propofol requirements, haemodynamic variables and postoperative pain relief in gynaecological surgery. Br J Anaesth. 2006 Feb;96(2):247-52. doi: 10.1093/bja/aei291. Epub 2005 Nov 25.
Reference Type
BACKGROUND
Ryu JH, Kang MH, Park KS, Do SH. Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous anaesthesia. Br J Anaesth. 2008 Mar;100(3):397-403. doi: 10.1093/bja/aem407.
Reference Type
BACKGROUND
Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7. doi: 10.1097/00000542-199602000-00011.
Reference Type
BACKGROUND
Song JW, Lee YW, Yoon KB, Park SJ, Shim YH. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. Anesth Analg. 2011 Aug;113(2):390-7. doi: 10.1213/ANE.0b013e31821d72bc. Epub 2011 May 19.
Reference Type
BACKGROUND
Tugrul S, Degirmenci N, Eren SB, Dogan R, Veyseller B, Ozturan O. Analgesic effect of magnesium in post-tonsillectomy patients: a prospective randomised clinical trial. Eur Arch Otorhinolaryngol. 2015 Sep;272(9):2483-7. doi: 10.1007/s00405-014-3219-8. Epub 2014 Aug 6.
Reference Type
BACKGROUND
Borazan H, Kececioglu A, Okesli S, Otelcioglu S. Oral magnesium lozenge reduces postoperative sore throat: a randomized, prospective, placebo-controlled study. Anesthesiology. 2012 Sep;117(3):512-8. doi: 10.1097/ALN.0b013e3182639d5f.
Reference Type
BACKGROUND
Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. Br J Anaesth. 2002 Nov;89(5):711-4.
Reference Type
BACKGROUND
Crosby V, Wilcock A, Corcoran R. The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage. 2000 Jan;19(1):35-9. doi: 10.1016/s0885-3924(99)00135-9.
Reference Type
BACKGROUND
Suresh S, Lozono S, Hall SC. Large-dose intravenous methotrexate-induced cutaneous toxicity: can oral magnesium oxide reduce pain? Anesth Analg. 2003 May;96(5):1413-1414. doi: 10.1213/01.ANE.0000057140.33744.65.
Reference Type
BACKGROUND
Kroin JS, McCarthy RJ, Von Roenn N, Schwab B, Tuman KJ, Ivankovich AD. Magnesium sulfate potentiates morphine antinociception at the spinal level. Anesth Analg. 2000 Apr;90(4):913-7. doi: 10.1097/00000539-200004000-00025.
Reference Type
BACKGROUND
Yousef AA, Al-deeb AE. A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component. Anaesthesia. 2013 Mar;68(3):260-6. doi: 10.1111/anae.12107. Epub 2012 Dec 17.
Reference Type
BACKGROUND
Lysakowski C, Dumont L, Czarnetzki C, Tramer MR. Magnesium as an adjuvant to postoperative analgesia: a systematic review of randomized trials. Anesth Analg. 2007 Jun;104(6):1532-9, table of contents. doi: 10.1213/01.ane.0000261250.59984.cd.
Reference Type
BACKGROUND
Pickering G, Morel V, Simen E, Cardot JM, Moustafa F, Delage N, Picard P, Eschalier S, Boulliau S, Dubray C. Oral magnesium treatment in patients with neuropathic pain: a randomized clinical trial. Magnes Res. 2011 Jun;24(2):28-35. doi: 10.1684/mrh.2011.0282.
Reference Type
BACKGROUND
Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain. 1996 Feb;64(2):283-291. doi: 10.1016/0304-3959(95)00113-1.
Reference Type
BACKGROUND
Mikkelsen S, Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. Effect of intravenous magnesium on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. Br J Anaesth. 2001 Jun;86(6):871-3. doi: 10.1093/bja/86.6.871.
Reference Type
BACKGROUND
Ruger LJ, Irnich D, Abahji TN, Crispin A, Hoffmann U, Lang PM. Characteristics of chronic ischemic pain in patients with peripheral arterial disease. Pain. 2008 Sep 30;139(1):201-208. doi: 10.1016/j.pain.2008.03.027. Epub 2008 May 9.
Reference Type
BACKGROUND
Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Rabinowitz B. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol. 2003 Mar 1;91(5):517-21. doi: 10.1016/s0002-9149(02)03297-6.
Reference Type
BACKGROUND
FONTAINE R, KIENY R, GANGLOFF JM, CUNY A, SUHLER A, GONZALES I, PARAMODIAZ M. LONG-TERM RESULTS OF RESTORATIVE ARTERIAL SURGERY IN OBSTRUCTIVE DISEASES OF THE ARTERIES. J Cardiovasc Surg (Torino). 1964 Nov-Dec;5:463-72. No abstract available.
Reference Type
BACKGROUND
Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002 Mar;23(3):239-55. doi: 10.1016/s0885-3924(01)00409-2.
Reference Type
BACKGROUND
Frampton CL, Hughes-Webb P. The measurement of pain. Clin Oncol (R Coll Radiol). 2011 Aug;23(6):381-6. doi: 10.1016/j.clon.2011.04.008. Epub 2011 May 14.
Reference Type
BACKGROUND
Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997 Feb;48(2):332-8. doi: 10.1212/wnl.48.2.332.
Reference Type
BACKGROUND
Bonezzi C, Nava A, Barbieri M, Bettaglio R, Demartini L, Miotti D, Paulin L. [Validazione della versione italiana del Brief Pain Inventory nei pazienti con dolore cronico]. Minerva Anestesiol. 2002 Jul-Aug;68(7-8):607-11. Italian.
Reference Type
BACKGROUND
Negri E, Bettaglio R, Demartini L, Allegri M, Barbieri M, Miotti D, Paulin L, Buonocore M, Bonezzi C. [Validation of the Italian version of the "Neuropathic Pain Scale" and its clinical applications]. Minerva Anestesiol. 2002 Mar;68(3):95-104. Italian.
Reference Type
BACKGROUND
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
Reference Type
BACKGROUND
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245-51. doi: 10.1016/0895-4356(94)90129-5.
Reference Type
BACKGROUND
Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-20.
Reference Type
BACKGROUND
Venturini MA, Zappa S, Minelli C, Bonardelli S, Lamberti L, Bisighini L, Zangrandi M, Turin M, Rizzo F, Rizzolo A, Latronico N. MAGnesium-oral supplementation to reduce PAin in patients with severe PERipheral arterial occlusive disease: the MAG-PAPER randomised clinical trial protocol. BMJ Open. 2015 Dec 16;5(12):e009137. doi: 10.1136/bmjopen-2015-009137.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1601 gluta-aos
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effect of Intraoperative Magnesium Sulfate Infusion on the Postoperative Recovery
NCT03206008
TERMINATED
NA
Effects of Intraoperative Magnesium Sulfate on Perioperative Pain Relief After Spine Surgery
NCT04161729
COMPLETED
PHASE4
Effect of Intraoperative Magnesium Infusion on Postoperative Pain and Cognitive Function
NCT04256057
UNKNOWN
EARLY_PHASE1
Magnesium Associated With Morphine for Cancer Pain Relief
NCT01541111
COMPLETED
NA
Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain
NCT02678117
COMPLETED
PHASE3
Magnesium and Postoperative Pain
NCT03253224
TERMINATED
PHASE4
Magnesium and TKA Pain
NCT01945437
UNKNOWN
NA
Safety and Efficacy of Intrathecally Administered Magnesium Sulfate
NCT03459417
COMPLETED
NA
Prescribing Vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients with Postoperative Pain:
NCT05370404
COMPLETED
NA
Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures
NCT02793947
COMPLETED
PHASE4
Intraoperative Magnesium Sulfate Administration During Orthotopic Liver Transplantation
NCT03717467
UNKNOWN
NA
the Effect of Doctor-nurse-patient Cooperative Analgesic Linkage Program on Movement Evoked Pain
NCT03823846
UNKNOWN
NA
Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery
NCT04391855
COMPLETED
PHASE4
Effect of Intrathecal Magnesium Sulfate Versus Intravenous Magnesium Sulfate on Postoperative Pain After Abdominal Hysterectomy
NCT06367595
NOT_YET_RECRUITING
PHASE2
Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.
NCT02527577
TERMINATED
NA
Correlation of Eicosanoid and Proresolving Lipid Mediator Temporal Profiles and Resolution of Pain After Thoracic Surgery
NCT03360175
UNKNOWN
Pain Management After Surgery
NCT05154682
UNKNOWN
PHASE3
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
NCT06602271
RECRUITING
PHASE3
Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Craniotomy Surgery Patients?
NCT05049707
UNKNOWN
PHASE3
Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients
NCT00608621
COMPLETED
Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen) for Elderly With Dementia
NCT00822224
COMPLETED
NA
Paravertebral Block vs no Block in Open Pancreaticoduodenectomy
NCT05820997
TERMINATED
PHASE4
Rectus Sheath Block: Postoperative Analgesia and Proinflammatory Cytokines
NCT03074097
COMPLETED
PHASE2
Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment
NCT02437929
COMPLETED
Postoperative Pain Alleviation in Open Heart Surgery
NCT03106818
COMPLETED
NA